<unk> , sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of<unk>  and<unk> . It is taken by mouth. The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . It was approved for use in the United States in January 2015, for use in the European Union in November 2016, and for use in Australia in December 2016.
Empagliflozin/linagliptin
Dapagliflozin/saxagliptin
Canagliflozin/metformin
Empagliflozin/metformin
Dapagliflozin/saxagliptin/metformin
Pioglitazone/metformin
Dapagliflozin/metformin
Pioglitazone/glimepiride